Daclatasvir is a highly selective NS5A replication complex inhibitor currently in development for the treatment of chronic hepatitis C infection. Daclatasvir is active at picomolar concentrations and demonstrates in vitro activity against a broad range of HCV genotypes. The primary objective of this study was to assess the effect of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate (Ortho Tri-Cyclen®).
Methods
In this open-label single-sequence study, 20 healthy female subjects received ethinyl estradiol and norgestimate for three cycles, with coadministration of daclatasvir in cycle 3. Pharmacokinetics of ethinyl estradiol and the active metabolites of norgestimate (norelgestromin and norgestrel) were assessed in cycles 2 and 3.
Results
Adjusted ratios of geometric means and 90% CIs were estimated for the maximum observed plasma concentration (ethinyl estradiol 1.11 [1.02, 1.20], norelgestromin 1.06 [0.99, 1.14] and norgestrel 1.07 [0.99, 1.16]) and area under the plasma concentration–time curve in one dosing interval (ethinyl estradiol 1.01 [0.95, 1.07], norelgestromin 1.12 [1.06, 1.17] and norgestrel 1.12 [1.02, 1.23]).
Conclusions
Coadministration of daclatasvir resulted in no clinically relevant effects on exposure to ethinyl estradiol, norelgestromin or norgestrel.
References
1.
NegroF., AlbertiA.The global health burden of hepatitis C virus infection. Liver Int2011; 31: 1–3.
2.
ArmstrongG.L., WasleyA., SimardE.P., McQuillanG.M., KuhnertW.L., AlterM.J.The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med2006; 144: 705–714.
3.
HadziyannisS.J., SetteH.Jr., MorganT.R.Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med2004; 140: 346–355.
4.
GhanyM.G., NelsonD.R., StraderD.B., ThomasD.L., SeeffL.B.An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guidelines by the American Association for the Study of Liver Diseases. Hepatology2011; 54: 1433–1444.
5.
DruytsE., MillsE.J., NachegaJ., O'ReganC., CooperC.L.Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis. Clin Exp Gastroenterol2012; 5: 11–21.
6.
JacobsonI.M., McHutchisonJ.G., DusheikoG.Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med2011; 364: 2405–2416.
7.
PoordadF., McConeJ., BaconB.R.Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med2011; 364: 1195–1206.
8.
Victrelis (boceprevir).Package insert2012. Merck & Co., Inc., NJ, USA.
9.
Incivek (telaprevir).Package insert2012. Vertex Pharmaceuticals IncorporatedMA, USA.
10.
WilbyK.J., GreanyaE.D., FordJ.A., YoshidaE.M., PartoviN.A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol2012; 11: 179–185.
11.
GargV., van HeeswijkR., LeeJ.E., AlvesK., NadkarniP., LuoX.Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology2011; 54: 20–27.
12.
HiraiS., HussainA., HaddadinM., SmithR.B.First-pass metabolism of ethinyl estradiol in dogs and rats. J Pharm Sci1981; 70: 403–406.
13.
GuengerichF.P.Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. Mol Pharmacol1988; 33: 500–508.
14.
WangB., SanchezR.I., FranklinR.B., EvansD.C., HuskeyS.E.The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos2004; 32: 1209–1212.
15.
EbnerT., RemmelR.P., BurchellB.Human bilirubin UDP-glucuronosyltransferase catalyzes the glucuronidation of ethinylestradiol. Mol Pharmacol1993; 43: 649–654.
16.
BukhJ., PietschmannT., LohmannV.Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. Proc Natl Acad Sci US2002; 99: 14416–14421.
17.
LindenbachB.D., RiceC.M.Unravelling hepatitis C virus replication from genome to function. Nature2005; 436: 933–938.
18.
GaoM., NettlesR.E., BelemaM.Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature2010; 465: 96–100.
19.
PolS., GhalibR.H., RustigV.K.Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis2012; 12: 671–677.
20.
EversonG.T., SimsK.D., Rodriguez-TorresM.Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology2014; 146: 420–429.
21.
SulkowskiM.S., GardinerD.F., Rodriguez-TorresM.Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med2014; 370: 211–221.
22.
ChayamaK., TakahashiS., ToyotaJ.Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology2012; 55: 742–748.
23.
LokA.S., GardinerD.F., LawitzE.Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med2012; 366: 216–224.
24.
Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.Department of Health and Human Services. (Accessed 8 June 2012). Available from http://aidsinfo.nih.gov/guidelines.
25.
ZhangJ., ChungE., YonesC.The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women. Antivir Ther2011; 16: 157–164.
26.
SekarV.J., LefebvreE., GuzmanS.S.Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women. Antivir Ther2008; 13: 563–569.
27.
SonodaJ., XieW., RosenfeldJ.M., BarwickJ.L., GuzelianP.S., EvansR.M.Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR). Proc Natl Acad Sci U S A2002; 99: 13801–13806.
28.
LuoG., CunninghamM., KimS.CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos2002; 30: 795–804.
29.
AndersonG.D.A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother1998; 32: 554–563.
30.
DavisA.R., WesthoffC.L., StanczykF.Z.Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding. Epilepsia2011; 52: 243–247.
31.
GargV., van HeeswijkR., YangY., KauffmanR., SmithF., AddaN.The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and the HCV protease inhibitor telaprevir. J Clin Pharmacol2012; 52: 1574–1583.
32.
Royal College of Obstetricians and Gynaecologists.Faculty of Sexual And Reproductive Healthcare clinical guidance. Drug interactions with hormonal contraception: clinical effectiveness unit. (Updated January 2012. Accessed October 2013.) Available from http://www.fsrh.org/pdfs/CEUguidancedruginteractionshormonal.pdf.
33.
NettlesR.E., GaoM., BifanoM.Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology2011; 54: 1956–1965.
